/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Business Of Biotech
  2. BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin
BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

Business Of Biotech · Jul 13, 2026

Dr. Jeremy Levin argues that biotech, a strategic asset, is in the balance, urging leaders to be outspoken and adopt a stakeholder-centric view.

Outspoken Biotech CEOs Strategically Purge Short-Term Shareholders

Speaking out on controversial issues isn't just a moral stance; it's a business strategy. It deters short-term, profit-driven shareholders a leader doesn't want, while attracting long-term investors who value transparency and a sustainable vision. This reframes risk into a filtering mechanism.

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin thumbnail

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

Business Of Biotech·2 days ago

Biotech's Current Crisis Is a Structural Assault, Not a Temporary Cycle

Ovid's Dr. Jeremy Levin argues that the convergence of public distrust in science, politicized funding, and agency turmoil represents a fundamental, structural threat. Unlike past cyclical downturns that eventually recover, these changes could permanently harm the US biotech ecosystem if they are not addressed directly.

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin thumbnail

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

Business Of Biotech·2 days ago

Big Pharma Deals in China Reveal Capital Migration, Not Just Competition

When a major US company like Bristol Myers Squibb invests in a Chinese biotech, it's not just a sign of global competition. It signifies a deliberate withdrawal of capital from the American biotech ecosystem. This migration of innovation and funding is a clear warning that the US is losing its strategic advantage.

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin thumbnail

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

Business Of Biotech·2 days ago

Board Chairs Must Flex Between Advisor and Hands-On 'Consultant CEO'

The role of a chairperson isn't static. At Ovid, Jeremy Levin acts as a traditional advisor. At Opthea, a company in turnaround, he became a 'consultant CEO'—downsizing the board and directly managing trial design and hiring. This demonstrates how board leadership must adapt to a company's specific situation.

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin thumbnail

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

Business Of Biotech·2 days ago

When a Clinical Trial Fails, Scrutinize the Core Science for a New Path

After Opthea's ophthalmology drug failed in trials, the company re-examined the underlying science of its VEGF-C/D mechanism instead of liquidating. This led to discovering a new application in a rare lung disease, proving that scientific assets can have value far beyond their initial intended use.

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin thumbnail

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

Business Of Biotech·2 days ago

A CEO's Job Is to Make Their Superior Hires Successful

Beyond simply hiring people smarter than oneself, a CEO's primary responsibility is to actively enable their success. This mindset shifts the focus from personal achievement to empowering the team, recognizing that the team's success is the ultimate driver of the company's and the CEO's own success.

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin thumbnail

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

Business Of Biotech·2 days ago

Leaders Must Discern if Criticism Is Valuable or Just 'Being Savaged by a Sheep'

Dr. Jeremy Levin offers a potent mental model for processing negative feedback. Leaders should listen carefully to all criticism but then quickly categorize it. Is it a valid point that offers value for improvement, or is it baseless noise? This allows leaders to stay open to feedback without being derailed by unproductive attacks.

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin thumbnail

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

Business Of Biotech·2 days ago